- Home
- CANG vs IPSC Comparison
CANG vs IPSC Comparison
Compare CANG & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANG
- IPSC
- Stock Information
- Founded
- CANG 2010
- IPSC 2019
- Country
- CANG China
- IPSC United States
- Employees
- CANG N/A
- IPSC N/A
- Industry
- CANG Computer Software: Prepackaged Software
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- CANG Technology
- IPSC Health Care
- Exchange
- CANG Nasdaq
- IPSC Nasdaq
- Market Cap
- CANG 153.4M
- IPSC 149.1M
- IPO Year
- CANG 2018
- IPSC 2021
- Fundamental
- Price
- CANG $1.53
- IPSC $1.59
- Analyst Decision
- CANG
- IPSC Strong Buy
- Analyst Count
- CANG 0
- IPSC 3
- Target Price
- CANG N/A
- IPSC $15.00
- AVG Volume (30 Days)
- CANG 20.2K
- IPSC 366.3K
- Earning Date
- CANG 08-29-2024
- IPSC 11-07-2024
- Dividend Yield
- CANG 100.00%
- IPSC N/A
- EPS Growth
- CANG N/A
- IPSC N/A
- EPS
- CANG 0.03
- IPSC N/A
- Revenue
- CANG $81,654,836.00
- IPSC $2,041,000.00
- Revenue This Year
- CANG $253.48
- IPSC $233.38
- Revenue Next Year
- CANG N/A
- IPSC $34.05
- P/E Ratio
- CANG $51.29
- IPSC N/A
- Revenue Growth
- CANG N/A
- IPSC N/A
- 52 Week Low
- CANG $0.92
- IPSC $1.28
- 52 Week High
- CANG $2.08
- IPSC $5.51
- Technical
- Relative Strength Index (RSI)
- CANG 36.34
- IPSC 44.33
- Support Level
- CANG $1.40
- IPSC $1.48
- Resistance Level
- CANG $1.67
- IPSC $1.63
- Average True Range (ATR)
- CANG 0.10
- IPSC 0.14
- MACD
- CANG -0.02
- IPSC 0.02
- Stochastic Oscillator
- CANG 30.98
- IPSC 34.70
About CANG Cango Inc. each representing two (2)
Cango Inc is an automotive transaction service platform in China connecting dealers, financial institutions, car buyers, and other industry participants. The services mainly consist of - automotive financing facilitation, automotive transaction facilitation, and aftermarket service facilitation. Geographically, it derives revenue from China.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.